Literature DB >> 35765522

Correlation of -475 IL-2 Promoter Gene Polymorphisms and the Levels of Serum IL-2 on the Risk of Multiple Sclerosis.

Thekra Abdulaali Abed1, Anwar Ali Abdulla1.   

Abstract

Background: The aim of present study is to asset the IL-2 promoter gene (SNP -475) as a candidate gene for multiple sclerosis (MS) susceptibility.
Methods: This study included 70 patients with relapsing - remitting multiple sclerosis (RRMS) and 50 healthy controls. Following the extraction of genomic DNA from peripheral blood, frequency of genotypes and alleles of SNP -475 was calculated using Restriction fragment length polymorphism-polymer chain reaction (RFLP-PCR) and then the results were analyzed statistically.
Results: The results revealed the unusual ratio for the heterozygous (AT) was 1.6972 indicating that heterozygous patients were at higher risk of multiple sclerosis than wild homozygous (AA), and homomutant (TT). The results show protective role for - 475 IL-2 promoter among individuals with multiple sclerosis, (O.R: 0.4872; C.I. 95%: 0.1617- 1.4680) and (O.R: 0.9275; C.I. 95%: 0.2476 - 3.4745) for both AA and TT genotypes, respectively.
Conclusion: Our results showed that in this population of Iraqi patients, the AT genotype / A allele of -475 IL-2 promoter gene SNP may include attributed factors for MS predisposition.

Entities:  

Keywords:  IL-2; Multiple sclerosis; PCR-RFLP SNP

Year:  2022        PMID: 35765522      PMCID: PMC9208566          DOI: 10.52547/rbmb.11.1.83

Source DB:  PubMed          Journal:  Rep Biochem Mol Biol        ISSN: 2322-3480


  27 in total

1.  Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity.

Authors:  Paul Browne; Dhia Chandraratna; Ceri Angood; Helen Tremlett; Chris Baker; Bruce V Taylor; Alan J Thompson
Journal:  Neurology       Date:  2014-09-09       Impact factor: 9.910

2.  The interleukin-2 T-cell system: a new cell growth model.

Authors:  D A Cantrell; K A Smith
Journal:  Science       Date:  1984-06-22       Impact factor: 47.728

Review 3.  Multiple sclerosis, a cause of secondary osteoporosis? What is the evidence and what are the clinical implications?

Authors:  M T Kampman; E F Eriksen; T Holmøy
Journal:  Acta Neurol Scand Suppl       Date:  2011

4.  Interleukin 1 and 2 production by peripheral blood mononuclear cells in subacute sclerosing panencephalitis and exacerbation of multiple sclerosis.

Authors:  W Brajczewska-Fischer; B Iwińska; J Kruszewska; J Korlak; A Członkowska
Journal:  Acta Neurol Scand       Date:  1989-11       Impact factor: 3.209

5.  Multiple sclerosis.

Authors:  Janice Charles; Lisa Valenti; Helena Britt
Journal:  Aust Fam Physician       Date:  2011-12

6.  Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients.

Authors:  P Gallo; M Piccinno; S Pagni; B Tavolato
Journal:  Ann Neurol       Date:  1988-12       Impact factor: 10.422

Review 7.  Revised diagnostic criteria of multiple sclerosis.

Authors:  Ron Milo; Ariel Miller
Journal:  Autoimmun Rev       Date:  2014-01-12       Impact factor: 9.754

8.  A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum.

Authors:  P Gallo; M G Piccinno; B Tavolato; A Sidén
Journal:  J Neurol Sci       Date:  1991-02       Impact factor: 3.181

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  The association of -475 and -631 interleukin-2 gene polymorphism with multiple sclerosis in Iranian patients.

Authors:  Aida Sayad; Abdolamir Allameh; Arezou Sayad; Mehrdad Noruzinia; Mohammad Taghi Akbari; Ali Sarzaeem; Akbari Akbar; Reza Haji Hoseini
Journal:  Cell J       Date:  2013-07-02       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.